Pharmaceutical Technology on MSN
FDA approves Acadia’s Daybue Stix for Rett syndrome
Daybue Stix will become available in limited quantities from the first quarter of 2026.
H.C. Wainwright raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $32 and keeps a Buy rating on the shares following the ...
ACADIA Pharmaceuticals generates revenue primarily through the commercialization of NUPLAZID for Parkinson's disease ...
Acadia Healthcare stock fell after revising its 2025 outlook due to higher litigation costs stemming from patient-related ...
Acadia Pharmaceuticals Inc. is rated a Buy for its steady NUPLAZID/DAYBUE franchises & pipeline-driven upside potential. Read ...
Although renowned for dozens of spectacular peaks, Acadia National Park on Mount Desert Island has more than outstanding ...
Travel + Leisure on MSN
This Easy Hike in Acadia National Park Is One of Its Most Scenic—With Peaceful Forest, a Mirror-like Lake, and Mountain Backdrops
The Jordan Pond Path is a favorite among visitors for a reason.
An Acadia Parish man who was wanted on numerous serious charges, injuring an Acadia Parish sheriff’s deputy and damaging ...
Acadia Healthcare faces rising legal, insurance, and compliance costs and a Medicaid-heavy payer mix under policy pressure.
14d
Bar Harbor businesses fear economic hit as Acadia National Park adds $100 fee for non-US tourists
A new $100 surcharge for non-U.S. visitors to Acadia and other national parks raises alarm among Bar Harbor businesses. BAR ...
Friends of Acadia estimates the park lost about $1.75M in entry revenue in October 2025 alone, not to mention the first two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback